{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:45:58Z","timestamp":1775490358165,"version":"3.50.1"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>IMPORTANCE:<\/jats:title>\n            <jats:p>Angiotensin II (ATII) was approved for septic or other distributive shock due to its property of increasing blood pressure within 3 hours. Limited data exist regarding its effectiveness when used in real-world clinical practice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>This study examined ATII as a third-line vasopressor based on institutional approval.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN:<\/jats:title>\n            <jats:p>Retrospective observational cohort study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SETTING AND PARTICIPANTS:<\/jats:title>\n            <jats:p>Medical ICU at an academic tertiary care medical center. Adult patients requiring 3 or more vasopressor agents for septic shock or other forms of distributed shock from September 1, 2018, to January 31, 2020.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MAIN OUTCOMES AND MEASURES:<\/jats:title>\n            <jats:p>Effect of ATII after norepinephrine and vasopressin on mortality and mean arterial blood pressure response after 3 hours of administration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>One-hundred forty-seven patients, 56 receiving ATII and 91 receiving another vasopressor (non-ATII), were enrolled. Patients in the ATII group had higher mortality compared to the non-ATII group, and more required 5 or greater vasopressor agents (<jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.01). After propensity score weighting, there remains a trend in higher mortality in the ATII compared to non-ATII group, but not statistically significant (86.0% vs 71.0%, <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.16). More patients in the ATII group continued to require 5 or greater vasopressor agents compared to the non-ATII group after propensity score weighting (45.9% vs 12.5%, <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; 0.01). SOFA score was the only variable associated with mortality (OR = 1.25, 95% CI, 1.05\u20131.49; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.01). Patients were considered a \u201cresponder\u201d if mean arterial pressure greater than 65 mm Hg at 3 hours after the third vasopressor was initiated. Among the ATII group, 37.5% patients were responders compared to 45.1% responders in the non-ATII group (relative risk = 1.07, 95% CI, 0.6\u20131.93; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.81).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS AND RELEVANCE:<\/jats:title>\n            <jats:p>Although previous data support the use of ATII due to its favorable hemodynamic response in patients with distributive shock, there was no observed benefit in mortality or hemodynamic response with ATII as a third-line vasopressor in our study of real-world patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cce.0000000000000623","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T19:02:05Z","timestamp":1642791725000},"page":"e0623","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Effectiveness of Angiotensin II for Catecholamine Refractory Septic or Distributive Shock on Mortality: A Propensity Score Weighted Analysis of Real-World Experience in the Medical ICU"],"prefix":"10.1097","volume":"4","author":[{"given":"Michele","family":"Quan","sequence":"first","affiliation":[{"name":"Division of Pulmonary, Critical Care, Hyperbaric, Allergy, and Sleep Medicine, Department of Medicine, Loma Linda University, Loma Linda, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nam","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Loma Linda University, Loma Linda, CA."},{"name":"Department of Pharmacy, Loma Linda University Medical Center, Loma Linda, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Bushell","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Loma Linda University, Loma Linda, CA."},{"name":"Department of Pharmacy, Loma Linda University Medical Center, Loma Linda, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Mak","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of California, Riverside, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nolan","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Division of Biological Sciences, University of California, San Diego, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Litwak","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, HonorHealth John C. Lincoln Medical Center, Phoenix, AZ."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Rockwood","sequence":"additional","affiliation":[{"name":"Division of Interdisciplinary Studies, Loma Linda University, Loma Linda, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Bryant","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care, Hyperbaric, Allergy, and Sleep Medicine, Department of Medicine, Loma Linda University, Loma Linda, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"key":"R1-20240807","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(15)70112-X","article-title":"Sepsis: A roadmap for future research.","volume":"15","author":"Cohen","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"R2-20240807","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3).","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"R3-20240807","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s13054-018-2144-4","article-title":"Refractory septic shock: Our pragmatic approach.","volume":"22","author":"Nandhabalan","year":"2018","journal-title":"Crit Care"},{"key":"R4-20240807","first-page":"654708","article-title":"Therapeutic strategies for high-dose vasopressor-dependent shock.","volume":"2013","author":"Bassi","year":"2013","journal-title":"Crit Care Res Pract"},{"key":"R5-20240807","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jpainsymman.2016.12.333","article-title":"Intensity of vasopressor therapy for septic shock and the risk of in-hospital death.","volume":"53","author":"Brand","year":"2017","journal-title":"J Pain Symptom Manage"},{"key":"R6-20240807","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/SHK.0000000000001022","article-title":"Vasopressor cumulative dose requirement and risk of early death during septic shock: An analysis from the EPISS cohort.","volume":"49","author":"Dargent","year":"2018","journal-title":"Shock"},{"key":"R7-20240807","doi-asserted-by":"crossref","first-page":"R181","DOI":"10.1186\/cc8167","article-title":"Association of arterial blood pressure and vasopressor load with septic shock mortality: A post hoc analysis of a multicenter trial.","volume":"13","author":"D\u00fcnser","year":"2009","journal-title":"Crit Care"},{"key":"R8-20240807","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa1312173","article-title":"High versus low blood-pressure target in patients with septic shock.","volume":"370","author":"Asfar","year":"2014","journal-title":"N Engl J Med"},{"key":"R9-20240807","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/s00134-012-2531-2","article-title":"Adverse cardiac events during catecholamine vasopressor therapy: A prospective observational study.","volume":"38","author":"Schmittinger","year":"2012","journal-title":"Intensive Care Med"},{"key":"R10-20240807","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/MCC.0000000000000517","article-title":"Vasodilatory shock in the ICU and the role of angiotensin II.","volume":"24","author":"Wakefield","year":"2018","journal-title":"Curr Opin Crit Care"},{"key":"R11-20240807","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2796.2008.01981.x","article-title":"Renin-angiotensin system revisited.","volume":"264","author":"Fyhrquist","year":"2008","journal-title":"J Intern Med"},{"key":"R12-20240807","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.amjmed.2003.09.034","article-title":"The renin-angiotensin-aldosterone system and the kidney: Effects on kidney disease.","volume":"116","author":"Brewster","year":"2004","journal-title":"Am J Med"},{"key":"R13-20240807","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/SHK.0000000000000807","article-title":"Angiotensin II in refractory septic shock.","volume":"47","author":"Antonucci","year":"2017","journal-title":"Shock"},{"key":"R14-20240807","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","article-title":"Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021.","volume":"49","author":"Evans","year":"2021","journal-title":"Crit Care Med"},{"key":"R15-20240807","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJMoa1704154","article-title":"Angiotensin II for the treatment of vasodilatory shock.","volume":"377","author":"Khanna","year":"2017","journal-title":"N Engl J Med"},{"key":"R16-20240807","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine.","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"key":"R17-20240807","first-page":"43","article-title":"Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3): Protocol for a phase III, double-blind, randomised controlled trial.","volume":"19","author":"Chawla","year":"2017","journal-title":"Crit Care Resusc"},{"key":"R18-20240807","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa067373","article-title":"Vasopressin versus norepinephrine infusion in patients with septic shock.","volume":"358","author":"Russell","year":"2008","journal-title":"N Engl J Med"},{"key":"R19-20240807","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0895-4356(00)00321-8","article-title":"Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: A matched analysis using propensity scores.","volume":"54","author":"Normand","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"R20-20240807","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/01621459.2016.1260466","article-title":"Balancing covariates via propensity score weighting.","volume":"113","author":"Li","year":"2018","journal-title":"J Am Stat Assoc"},{"key":"R21-20240807","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/jama.2020.7819","article-title":"Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial.","volume":"323","author":"Thomas","year":"2020","journal-title":"JAMA"},{"key":"R24-20240807","first-page":"67","article-title":"mice: Multivariate imputation by chained equations in R.","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw"},{"key":"R25-20240807","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10654-018-0447-z","article-title":"A comparison of different methods to handle missing data in the context of propensity score analysis.","volume":"34","author":"Choi","year":"2019","journal-title":"Eur J Epidemiol"},{"key":"R26-20240807","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1146\/annurev.clinpsy.032408.153550","article-title":"Advances in analysis of longitudinal data.","volume":"6","author":"Gibbons","year":"2010","journal-title":"Annu Rev Clin Psychol"},{"key":"R27-20240807","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1186\/s13054-014-0534-9","article-title":"Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): A pilot study.","volume":"18","author":"Chawla","year":"2014","journal-title":"Crit Care"},{"key":"R28-20240807","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40560-020-00500-0","article-title":"Non-catecholamine vasopressors in the treatment of adult patients with septic shock-evidence from meta-analysis and trial sequential analysis of randomized clinical trials.","volume":"8","author":"Zhong","year":"2020","journal-title":"J Intensive Care"},{"key":"R29-20240807","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.chest.2020.08.2074","article-title":"Angiotensin II infusion for shock: A multicenter study of postmarketing use.","volume":"159","author":"Wieruszewski","year":"2021","journal-title":"Chest"},{"key":"R30-20240807","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/0885066620972943","article-title":"A multicenter observational cohort study of angiotensin II in shock.","volume":"37","author":"Smith","year":"2022","journal-title":"J Intensive Care Med"},{"key":"R31-20240807","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/1089253219877876","article-title":"Angiotensin II in decompensated cirrhosis complicated by septic shock.","volume":"24","author":"Coleman","year":"2020","journal-title":"Semin Cardiothorac Vasc Anesth"},{"key":"R32-20240807","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1177\/0885066619872720","article-title":"A retrospective review of angiotensin II use in adult patients with refractory distributive shock.","volume":"35","author":"Wong","year":"2020","journal-title":"J Intensive Care Med"},{"key":"R33-20240807","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.athoracsur.2018.11.047","article-title":"Use of angiotensin II for post cardiopulmonary bypass vasoplegic syndrome.","volume":"108","author":"Evans","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"R34-20240807","doi-asserted-by":"crossref","first-page":"e0434","DOI":"10.1097\/CCE.0000000000000434","article-title":"Angiotensin II for near drowning: A case series.","volume":"3","author":"Smith","year":"2021","journal-title":"Crit Care Explor"},{"key":"R35-20240807","doi-asserted-by":"crossref","first-page":"e01402","DOI":"10.1213\/XAA.0000000000001402","article-title":"Intraoperative use of angiotensin II for severe vasodilatory shock during liver transplantation: A case report.","volume":"15","author":"Running","year":"2021","journal-title":"A A Pract"},{"key":"R36-20240807","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.chest.2020.04.015","article-title":"Unexpected BP sensitivity to angiotensin II in a patient with coronavirus disease 2019, ARDS, and septic shock.","volume":"158","author":"Wang","year":"2020","journal-title":"Chest"},{"key":"R37-20240807","article-title":"Angiotensin II: A review of current literature.","author":"Alam","year":"2021 Jul 16","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R38-20240807","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jcrc.2019.10.005","article-title":"Cost-effectiveness of second-line vasopressors for the treatment of septic shock.","volume":"55","author":"Lam","year":"2020","journal-title":"J Crit Care"},{"key":"R39-20240807","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1164\/rccm.201911-2172OC","article-title":"Renin and survival in patients given angiotensin II for catecholamine-resistant vasodilatory shock. A clinical trial.","volume":"202","author":"Bellomo","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"R40-20240807","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3892\/etm.2014.1566","article-title":"Severe sepsis: Low expression of the renin-angiotensin system is associated with poor prognosis.","volume":"7","author":"Zhang","year":"2014","journal-title":"Exp Ther Med"},{"key":"R41-20240807","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1186\/cc1822","article-title":"Clinical review: Myocardial depression in sepsis and septic shock.","volume":"6","author":"Court","year":"2002","journal-title":"Crit Care"}],"container-title":["Critical Care Explorations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000623","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T14:33:03Z","timestamp":1723041183000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cce.0000000000000623","relation":{},"ISSN":["2639-8028"],"issn-type":[{"value":"2639-8028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}